Print

Purpose

The study is divided into two parts. The first part of the study will test various doses of ASN007 to find out the highest safe dose to test in five specific groups. The second part of the study will test how well ASN007 can control cancer.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Written informed consent obtained prior to any study-related procedure being performed; - Male or non-pregnant, non-lactating female patient at least 18 years of age at the time of consent; - Eastern Cooperative Oncology Group Performance Status 0-1 (Part A) and PS 0-2 (Part B) - Histologically or cytologically confirmed - advanced or metastatic solid tumor (Part A) - Group 1: BRAF mutant melanoma (Part B) - Group 2: NRAS or HRAS mutant solid tumors(Part B) - Group 3: KRAS mutant CRC.(Part B) - Group 4: KRAS mutant NSCLC (Part B) - Group 5: Pancreatic Ductal Adenocarcinoma (Part B) - Progressive disease after failure of or intolerant to all available standard systemic treatments that have shown a documented benefit in overall survival for their respective tumor type. - Measurable or evaluable disease per RECIST v1.1 - Screening hematology values of the following: - absolute neutrophil count ≥ 1000/μL, - platelets ≥ 100,000/μL, - hemoglobin ≥ 9 g/dL - Screening chemistry values of the following: - alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 3.0 × upper limit of the normal (ULN), - total bilirubin ≤ 1.5 × ULN, - creatinine ≤ 1.5 × ULN,, - albumin ≥ 2.8 g/dL. - Screening heart function lab test - creatinine kinase - MB, troponin-I, and troponin-T within normal limits - Subject is willing and able to comply with all protocol required visits and assessments, including biopsy if assigned.

Exclusion Criteria

  • Prior treatment with ASN007 or another ERK1/2 inhibitor - Known hypersensitivity to ASN007 or its excipients; - Part B: Prior treatment with a RAF or MEK pathway inhibitor, except BRAFmutant melanoma (Group 1) - Prior chemotherapy, targeted therapy or monoclonal antibody therapy within 3 weeks of start of study treatment (Day1), or 5 half-lives, whichever is shorter. - Concurrent or prior bone marrow factors (e.g. G-CSF, GM-CSF or erythropoietin) within 3 weeks prior to Day 1 of treatment. - Febrile neutropenia or serious persistent infection within 2 weeks prior to Day 1 of treatment - Failure to recover from major surgery or traumatic injury within 4 weeks or minor surgery within 2 weeks prior to Day 1 of treatment. - History of or current evidence / risk of retinal vein occlusion (RVO) central serous retinopathy (CSR), or glaucoma with intraocular pressures ≥ 21 mmHg or other pre-existing ocular conditions that may put the patient at risk for ocular toxicities - Known central nervous system (CNS) primary tumor, CNS metastases or carcinomatous meningitis (Part A). Patients may be enrolled with CNS metastasis in certain circumstances in Part B. - Clinically significant heart disorders including an ejection fraction of < 50% - Other serious uncontrolled conditions such as fungal, bacterial or viral infection; HIV, Hepatitis B or C, bleeding disorders, interstitial lung disease, - Any other condition that might place the patient at undue risk.

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
ASN007 ascending doses 		Patients will receive escalating doses of ASN007 to identify the best dose.
  • Drug: ASN007: ascending doses
    Oral drug for the treatment of advanced solid tumors
Experimental
ASN007 RD: KRAS mutant Melanoma 		Patients with BRAF mutant metastatic melanoma will receive the recommended dose from Part A.
  • Drug: ASN007 RD
    Oral drug for the treatment of advanced solid tumors
Experimental
ASN007 RD: NRAS mutant Melanoma 		Patients with NRAS and HRAS mutant solid tumors will receive the recommended dose from Part A.
  • Drug: ASN007 RD
    Oral drug for the treatment of advanced solid tumors
Experimental
ASN007 RD: KRAS mutant metastatic CRC 		Patients with KRAS mutant CRC will receive the recommended dose from Part A
  • Drug: ASN007 RD
    Oral drug for the treatment of advanced solid tumors
Experimental
ASN007 RD: KRAS mutant NSCLC 		Patients with KRAS mutant NSCLC will receive the recommended dose from Part A
  • Drug: ASN007 RD
    Oral drug for the treatment of advanced solid tumors
Experimental
ASN007 RD: Metastatic Pancreatic Cancer 		Patients with pancreatic adenocarcinoma will receive the recommended dose from Part A
  • Drug: ASN007 RD
    Oral drug for the treatment of advanced solid tumors
Experimental
ASN007 RD: MEK, All BRAF, BRAF-fusion cancers 		Patients with solid tumors will receive the recommended dose from Part A
  • Drug: ASN007 RD
    Oral drug for the treatment of advanced solid tumors

More Details

Status
Completed
Sponsor
Asana BioSciences

Study Contact

Detailed Description

Part A is a dose escalation study to determine a safe and tolerable dose of ASN007 for patients with advanced solid tumors. Part A will also describe how the body works on ASN007(pharmacokinetics) and the effects of ASN007 on the body (pharmacodynamics) of ASN007, through blood sampling and optional biopsies.. Part B of the study will enroll patients with particular tumor types and genetic mutations for treatment at the Recommended Phase 2 Dose. Part B will enroll patients in five groups of fifteen patients each: Group 1: Patients with metastatic BRAF mutated melanoma Group 2: Patients with metastatic NRAS and HRAS mutated solid tumors Group 3: Patients with metastatic KRAS mutated colorectal cancer (CRC) Group 4: Patients with metastatic KRAS mutated non-small cell lung cancer (NSCLC) Group 5: Patients with metastatic pancreatic ductal adenocarcinoma (PDAC) Patients with melanoma will be required to have pre-dose and post-dose biopsies. Group 6: Patients with metastatic MEK1, BRAF V600E, non-BRAF V600E solid tumors or BRAF fusions without prior treatment with BRAF, MEK, ERK inhibitors

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.